Rubicon Research Limited IPO has become one of the most talked-about issues in the pharmaceutical segment this week. With strong fundamentals, growing exports, and robust grey market activity, investors are closely tracking the Rubicon Research IPO GMP (Grey Market Premium) for potential listing gains.
Below is the complete day-wise Rubicon Research IPO GMP trend, issue details, and expert market analysis.
Rubicon Research IPO GMP Trend
Below is the latest Grey Market Premium (GMP) trend for Rubicon Research IPO, showing daily movement, estimated listing price, and expected profit for retail investors:
| GMP Date | GMP | Estimated Listing Price | Estimated Profit* |
|---|---|---|---|
| 13-10-2025 | ₹95 | ₹580 (19%) | ₹2850 |
| 12-10-2025 | ₹108 | ₹593 (22.27%) | ₹3,240 |
| 11-10-2025 | ₹110 | ₹595 (22.68%) | ₹3,300 |
| 10-10-2025 | ₹111 | ₹596 (22.89%) | ₹3,330 |
| 09-10-2025 | ₹98 | ₹583 (21%) | ₹2,940 |
| 08-10-2025 | ₹92 | ₹577 (18.97%) | ₹2,760 |
| 07-10-2025 | ₹80 | ₹565 (16.49%) | ₹2,400 |
| 06-10-2025 | ₹80 | ₹565 (16.49%) | ₹2,400 |
| 05-10-2025 | ₹68 | ₹553 (14.02%) | ₹2,040 |
| 04-10-2025 | ₹60 | ₹545 (12.37%) | ₹1,800 |
Note: GMP data is sourced from grey market reports and may vary daily. It is not an official indicator and should be used only for reference.
Rubicon Research IPO Details
| Particulars | Details |
|---|---|
| IPO Open Date | October 9, 2025 |
| IPO Close Date | October 13, 2025 |
| Issue Price | ₹461 – ₹485 per share |
| Face Value | ₹1 per equity share |
| Issue Size | ₹1,377.50 crore |
| Fresh Issue | ₹500 crore |
| Offer for Sale (OFS) | ₹877.50 crore |
| Issue Type | Book Built Issue |
| Listing At | NSE, BSE |
| Registrar | Link Intime India Pvt Ltd |
| Basis of Allotment | October 14, 2025 |
| Refunds Initiation | October 15, 2025 |
| Shares Credit to Demat | October 15, 2025 |
| Listing Date | October 16, 2025 |
What Does the GMP Indicate?
The rising GMP trend for Rubicon Research IPO indicates strong investor sentiment and increasing demand in the grey market.
With a GMP of ₹95 on the last update (13-Oct-2025), the stock is expected to list around ₹580 — approximately 19% above the issue price.
About Rubicon Research Limited
Rubicon Research Limited is a pharmaceutical product development and manufacturing company specialising in complex generics and drug delivery systems.
Key Highlights:
- Over 100 patents filed globally.
- R&D-driven business model with facilities in Thane and Ambernath, Maharashtra.
- Serves regulated markets like the US, Europe, and Canada.
- Steady revenue growth and profitability in the past three years.
The IPO proceeds will be used to repay debt, fund R&D expansion, and strengthen manufacturing capacity.
Rubicon Research IPO Financial Performance
| Financial Year | Revenue (₹ Cr) | EBITDA (₹ Cr) | PAT (₹ Cr) |
|---|---|---|---|
| FY2022 | 625 | 112 | 48 |
| FY2023 | 690 | 125 | 52 |
| FY2024 | 765 | 138 | 60 |
The company’s profit margins and exports have improved consistently, showcasing operational efficiency and R&D strength.
Analyst View On Rubicon Research IPO
Experts believe that the Rubicon Research IPO offers medium-term growth potential due to its strong fundamentals and expanding global reach. The GMP uptrend reflects positive listing expectations; however, investors are advised to carefully evaluate valuations before applying.
Conclusion
The Rubicon Research IPO GMP trend is clearly upward, showing increasing investor confidence. With a stable financial profile and rising demand in the grey market, the IPO is expected to see a profitable listing if market conditions remain strong.
Still, investors should rely on official filings and personal analysis before making investment decisions
Share
